PLEASANTON, Calif., Sept. 14 Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that will be participating in the UBS Global Life Sciences Conference on Tuesday, September 22.
David V. Smith, executive vice president and chief financial officer, will provide an update on the company beginning at 11:30 a.m., Eastern Daylight Time (8:30 a.m., Pacific Daylight Time).
The presentation will be available through the conference website at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=57_02G520B, or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's websites at http://www.thoratec.com or http://www.itcmed.com.
SOURCE Thoratec Corporation